A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Inclusion Criteria:

- patients at least 18 years of age with moderate to severe active RA for at least 6
months;

- inadequate response to current anti-rheumatic therapies, including 1 or more
traditional DMARDs;

- stable DMARD therapy for at least 8 weeks before entering study;

- patients of reproductive potential must be using reliable methods of contraception.

Exclusion Criteria:

- major surgery (including joint surgery) within 8 weeks before entering study, or
planned surgery within 6 months after entering study;

- patients who have previously failed treatment with an anti-tumor necrosis factor
agent;

- women who are pregnant or breast-feeding.